Brief Description
The KIND study is testing the safety, efficacy, and pharmacokinetics of paricalcitol oral solution in participants of ages 0 to 9 years that have been diagnosed with Secondary Hyperparathyroidism (SHPT) associated with stage 5 Chronic Kidney Disease (CKD) receiving Peritoneal Dialysis (PD) or Hemodialysis (HD).
Estimated Enrollment
16 patients
Estimated End Date
February 2027
Trial is for people with
2-9 years old patients diagnosed with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) stage 5 receiving ...
Study Goal
The goal of the study is to assess the effect of Paracalcitol on blood calcium levels and intact parathyroid hormone (iPTH) in ...
What is involved for the patient?
Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks.
About the drug or intervention
Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser.